Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button


Home > Press > University College London and Ondine Biopharma Announce Breakthrough Staphyloccocal Photodisinfection Technology

- Most potent photodisinfection agent known today -

University College London and Ondine Biopharma Announce Breakthrough Staphyloccocal Photodisinfection Technology

LONDON, UK and VANCOUVER, Canada | Posted on October 9th, 2007

UCL Business PLC, and Ondine Biopharma Corporation (TSX: OBP; AIM: OBP) today announced an important
advance in photo-disinfection technology used to kill staphylococci such as methicillin-resistant Staphylococcus aureus (MRSA). In a multi-year collaborative research effort, scientists developed a nanotechnology-based photosensitizer that dramatically enhanced antimicrobial lethality at very small unit doses. The results of the research were published in the Royal Society of Chemistry's Journal of Materials Chemistry, 2007, 17, 3739-3746 and, because of the importance of the advancement, this publication has been selected for inclusion in the Royal Society of Chemistry's journal Chemical Biology Research Articles.

"The new nanoparticle photosensitizer is the most potent light-activated
antimicrobial agent known to date," said Dr. Cale Street, Director of
Research, Ondine Biopharma. "By covalently attaching gold nanoclusters to an
existing photosensitizer, we were able to dramatically boost bacterial killing
efficacy. We can now use very low concentrations of photosensitizer to achieve
greater than 99.99% eradication of bacteria in seconds to minutes, improving
our ability to develop photodisinfection-based products for the clinical
treatment of infections in wounds, burns, and other conditions."

"This development is the culmination of an intensive, cross-functional
research effort to develop next-generation anti-MRSA photodisinfection
agents," said Professor Michael Wilson, Division of Microbial Diseases,
University College London. "As resistance to antibiotics continues to increase
in most of the major human pathogens, this powerful technology has great
potential in the struggle against the growing prevalence of hospital-acquired

Ondine Biopharma owns exclusive rights to worldwide patent applications
covering this photodisinfection technology. With widespread antimicrobial
indications including eradication of MRSA from the nose and other areas,
treatment of conditions such as periodontal diseases, otitis externa, nailbed
fungus and the disinfection of burns and wounds.


About CL Business PLC
UCL Business PLC (UCLB) is the organisation responsible for
commercializing research generated within University College London (UCL) and
associated organisations. It is primarily responsible for protecting
inventions and transacting commercial activity including options, licences and
collaborative commercial research associated with the University. UCLB also
has responsibility for creating and spinning-out companies from UCL. UCLB is
wholly-owned by UCL and operates as an independent company with its own Board
of Directors.

About Periowave(TM) and Photodisinfection

Periowave(TM) is a Photodisinfection system developed by Ondine that
utilizes low-intensity lasers and wavelength-specific, light-activated
photosensitive compounds to specifically target and destroy microbial
pathogens and reduce the symptoms of disease. The compounds are topically
applied and lasers of appropriate wavelength and intensity are used to
disinfect the treatment site. The Company's Periowave(TM) photodisinfection
system is currently approved in Canada for nasal eradication of pathogenic
bacteria such as MRSA and the oral treatment of periodontitis, gingivitis,
peri-implantitis, peri-mucositis, endodontics, and in the European Union for
nasal eradication of MRSA, adult periodontitis, endodontics and
peri-implantitis. The photodynamic disinfection technologies were developed by
Professor Michael Wilson and colleagues at the Eastman Dental Institute,
University College London, and licensed to Ondine by UCL Business PLC,
University College London. Full text of the research publication described
above can be found at J. Mater. Chem., 2007, 17, 3739-3746. Additional
information about Periowave(TM) is available at .

About Ondine Biopharma Corporation

Ondine is developing non-antibiotic therapies for the treatment of a
broad spectrum of bacterial, fungal and viral infections. The Company is
focused on creating and commercializing leading edge products utilizing its
patented light-activated technology. Photodisinfection provides broad-spectrum
antimicrobial efficacy without encouraging the formation and spread of
antibiotic resistance. The Company is headquartered in Vancouver, British
Columbia, Canada, with a research laboratory in Bothell, Washington, USA, and
an international office in St. Michael, Barbados. For additional information,
please visit the Company's website at:

Forward-Looking Statements:

Certain statements contained in this release containing words like
"believe", "intend", "may", "expect" and other similar expressions, are
forward-looking statements that involve a number of risks and uncertainties.
Factors that could cause actual results to differ materially from those
projected in the Company's forward-looking statements include the following:
market acceptance of our technologies and products; our ability to obtain
financing; our financial and technical resources relative to those of our
competitors; our ability to keep up with rapid technological change;
government regulation of our technologies; our ability to enforce our
intellectual property rights and protect our proprietary technologies; the
ability to obtain and develop partnership opportunities; the timing of
commercial product launches; the ability to achieve key technical milestones
in key products and other risk factors identified from time to time in the
Company's filings.

For more information, please click here

Carolyn Cross
President and Chief Executive
Ondine Biopharma Corporation
(604) 669-0555

Christina Bessant
Investor Relations
The Equicom Group Inc.
(416) 815-0700 ext. 269

Irma Gomez-Dib
Media & Investors Relations
FD International
(212) 850-5761

Nominated Adviser
Neil Johnson/Ryan Gaffney
Canaccord Adams Ltd
+44(0)20 7050 6500

Copyright © CNW Group Ltd.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press


Scientists 'see' detailed make-up of deadly toxin for the first time: Exciting advance provides hope for developing novel potential method of treating pneumococcal diseases such as bacterial pneumonia, meningitis and septicaemia November 25th, 2015

Electric fields remove nanoparticles from blood with ease November 24th, 2015

Production of Nanocapsules Containing Omega-3 Powder in Iran November 24th, 2015

Breakthrough allows tracking of single molecules in 3-D with nanoscale accuracy:New method builds on Nobel Prize-winning technique, with exciting implications for understanding the inner workings of cells and neurons November 23rd, 2015


New 'self-healing' gel makes electronics more flexible November 25th, 2015

Scientists design a QKD-based quantum private query with no failure November 25th, 2015

MIT mathematicians identify limits to heat flow at the nanoscale: New formula identifies limits to nanoscale heat transfer, may help optimize devices that convert heat to electricity November 25th, 2015

Physicists explain the unusual behavior of strongly disordered superconductors: Using a theory they developed previously, the scientists have linked superconducting carrier density with the quantum properties of a substance November 25th, 2015

Patents/IP/Tech Transfer/Licensing

Electric fields remove nanoparticles from blood with ease November 24th, 2015

Calling All Industries: Get Your Graphene By The Kiloton November 21st, 2015

Nanotech-based sensor developed to measure microRNAs in blood, speed cancer detection November 19th, 2015

Arrowhead Late-Breaking Clinical Data Shows that ARC-520 Can Produce Deep and Durable Reductions of Hepatitis B Viral Antigens and DNA November 16th, 2015

Research partnerships

MIT mathematicians identify limits to heat flow at the nanoscale: New formula identifies limits to nanoscale heat transfer, may help optimize devices that convert heat to electricity November 25th, 2015

New EU project designed to link diagnosis and treatment of diseases over the long term: Joint research project aims at the improvement of companion diagnostics and therapy of tumor diseases November 23rd, 2015

Nanocarriers may carry new hope for brain cancer therapy: Berkeley Lab researchers develop nanoparticles that can carry therapeutics across the brain blood barrier November 22nd, 2015

The route to high temperature superconductivity goes through the flat land: The route to high temperature superconductivity goes through the flat land November 21st, 2015

The latest news from around the world, FREE

  Premium Products
Only the news you want to read!
 Learn More
University Technology Transfer & Patents
 Learn More
Full-service, expert consulting
 Learn More

Nanotechnology Now Featured Books


The Hunger Project

Car Brands
Buy website traffic